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Abstract
Bone and mineral disorders occur frequently in kidney transplant recipients and are associated with a high risk of
fracture, morbidity, and mortality. There is a broad spectrum of often overlapping bone diseases seen after
transplantation, including osteoporosis as well as persisting high– or low–turnover bone disease. The patho-
physiology underlying bone disorders after transplantation results from a complex interplay of factors, including
preexisting renal osteodystrophy and bone loss related to a variety of causes, such as immunosuppression and
alterations in the parathyroid hormone-vitamin D-fibroblast growth factor 23 axis as well as changes in mineral
metabolism. Management is complex, because noninvasive tools, such as imaging and bone biomarkers, do not
have sufficient sensitivity and specificity to detect these abnormalities in bone structure and function, whereas
bone biopsy is not a widely available diagnostic tool. In this review, we focus on recent data that highlight
improvements in our understanding of the prevalence, pathophysiology, and diagnostic and therapeutic strategies
of mineral and bone disorders in kidney transplant recipients.
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Introduction
Bone disease post-transplantation is a major cause of
morbidity in kidney transplant recipients, with a sig-
nificantly higher risk of fractures as well as increased
health care costs, hospitalization, and mortality (1).
Post–transplantation bone disease is characterized by
changes in bone quality and density as well as mineral
metabolism, which contribute to increased fracture risk,
and therefore, post–transplantation bone disease is sig-
nificantly different from the range of chronic kidney
disease and mineral bone disorders (CKD-MBDs)
seen pretransplantation. In this review, we will discuss
the epidemiology, pathophysiology, and types of post–
transplantation bone disease, the role of imaging in
predicting fracture risk, and therapeutic strategies to
manage bone disease after transplantation.
Epidemiology
The spectrum of bone diseases in kidney transplant
recipients includes renal osteodystrophy, osteoporo-
sis, bone fracture, and osteonecrosis. Earlier studies
after transplantation indicate that bone mineral den-
sity (BMD) declines by 4%–10% in the ﬁrst 6 months
(2), with a further decrease of 0.4%–4.5% in lumbar
BMD between 6 and 12 months (3). More recent pub-
lications of prospective trials that included patients
managed with contemporary immunosuppression
protocols have reported bone loss of only 0.1%–
5.7% in the lumbar spine (4). After 1 year, BMD re-
mains relatively stable with no further decline but at
signiﬁcantly lower levels than healthy controls (2).
This reduction in BMD contributes to an increased
risk of fractures. In the ﬁrst 5 years after transplan-
tation, 22.5% of kidney transplant recipients
experience a fracture—an incidence that is four times
that in the general population (5). This risk remains sig-
niﬁcantly elevated even 10 years post-transplantation,
suggesting that bone remains fragile after transplan-
tation, despite improvement in parameters of mineral
metabolism (1). Risk factors for bone loss and frac-
tures are summarized in Table 1 (6). The fracture rate
among kidney transplant recipients is 34% higher in
the ﬁrst 3 years after transplantation, but thereafter,
the risk of fracture is lower than that in comparable
patients who remain on dialysis (7). The most com-
mon fracture locations are the hip and ankle/foot (6),
with hip fracture usually associated with osteoporosis.
Because the distal skeleton is an atypical site for oste-
oporotic fracture, the relatively high frequency of an-
kle/foot fracture probably reﬂects the fact that both
osteoporosis and renal osteodystrophy coexist post-
transplantation. Outcomes for kidney transplant recip-
ients who sustain a fracture are signiﬁcantly worse,
with a 60% increased risk in mortality compared
with the general population (6). The US Renal Data
System (USRDS) data show the importance of diabe-
tes, with the risk of fracture among men with diabe-
tes who underwent kidney-only transplantation
being 31% higher than those who had received a
simultaneous kidney-pancreas transplant (8), a ﬁnd-
ing consistent with recent microindentation studies
showing that patients with diabetes have both
reduced BMD and bone strength (9).
The rate of fracture has decreased in recent years,
with the USRDS data showing the incidence of hip
fracture to be 45% lower in patients transplanted in
2010 than in patients transplanted in 1997 (1), al-
though it is still higher than in the general population
(2). This trend partly reﬂects a signiﬁcant reduction in
cumulative glucocorticoid (GC) exposure, but this
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(10); other factors may be important, including improved
management of CKD-MBD pretransplantation and bone
protection strategies, such as vitamin D and bisphosphonates
in kidney transplant recipients, as well as changes in life-
style and physical activity. Despite the reduction in hip
fracture rates, outcomes after hip fracture are poor,
with a recent analysis of 21,769 kidney transplant recipients
in the United Kingdom indicating that a hip fracture was
independently associated with a threefold increase in
mortality risk (11).
Pathophysiology of Post–Transplant Bone Disease
Post–transplantation bone disease results from the evo-
lution of preexisting CKD-MBD but also, the development,
in some patients, of osteoporosis, and differentiating be-
tween these two often overlapping conditions is essential
for subsequent management (2).
There is rapid loss of bonemass in the early post–transplant
period that frequently affects trabecular bone because of
decreased bone formation as a result of GC therapy (12).
In contrast, before transplantation, bone loss preferen-
tially affects the cortical bone mainly because of second-
ary hyperparathyroidism (SHPT). The evolution of
post–transplantation bone disease is also modiﬁed by a va-
riety of post-transplant factors, including the use of immu-
nosuppressive drugs, the degree of graft dysfunction, and
disturbances in mineral metabolism, including an increased
level of ﬁbroblast growth factor 23, ongoing SHPT, and
vitamin D deﬁciency. Progressive loss of kidney function
after transplantation increases the risk of worsening or de
novo development of hyperparathyroidism with active
vitamin D deﬁciency that leads to changes in bone
histomorphometry similar to those observed before trans-
plantation (2). Ethnicity may also affect the type of renal
osteodystrophy seen after transplantation, because white
patients on dialysis are more likely to have low bone turn-
over than blacks (13). In the following sections, we will
discuss the effect of a number of factors in the development
of post–transplantation bone disease as highlighted in
Figure 1.
Evolution of Preexisting Renal Osteodystrophy
Preexisting renal osteodystrophy is a risk factor for
fracture and adverse outcomes post-transplantation (14).
The prevalence of histologic patterns of post–transplantation
bone disease is not well deﬁned, because there have been
very few bone biopsy studies in kidney transplant recip-
ients. Osteomalacia and adynamic bone disease (ABD)
were the two most common types of renal osteodystrophy
previously described (2); however, this may not represent
the contemporary spectrum of renal osteodystrophy seen
post-transplantation given the marked changes in both
the management of CKD-MBD and immunosuppressive
practice in recent years. In another cohort of 20 kidney trans-
plant recipients, ABD was the most common lesion seen on
bone biopsy 6 months post-transplantation (15), whereas
in a different series of 57 kidney transplant recipients
(biopsied at a mean interval of 53.5 months after transplan-
tation), osteitis ﬁbrosa (high–turnover bone disease) was the
most common histomorphometric lesion seen, with ABD
only affecting 5% of the kidney transplant recipients (16).
This discrepancy in bone biopsy data may reﬂect the differ-
ing time after transplantation that the biopsy was taken,
suggesting that bone disease continues to evolve for many
years after transplantation.
Osteoporosis and Effect of Immunosuppression on Bone
Osteoporosis is deﬁned as a reduction in bone mass
with microarchitectural deterioration of bone tissue and
subsequent increase in bone fragility and susceptibility
to fracture. Osteoporosis has also been deﬁned quantita-
tively using BMD and can be expressed as an SD score
comparing an individual’s BMD with that of a reference
population as measured by dual x-ray absorptiometry
(DXA). A T-score that is #22.5 (i.e., $2.5 SDs below
the mean BMD of a normal young–adult reference
population) is indicative of osteoporosis. Although GC
use remains the key risk factor for the development of
osteoporosis after transplantation, there are other factors
(summarized in Table 1) that contribute to the marked
bone loss seen after transplantation.
Table 1. Risks factors associated with post–transplantation
bone loss and fractures
Risk factors for osteoporosis
General factors








Functionally different alleles of the vitamin D
receptor gene
Risk factors for fracture
Skeletal factors
Lumbar osteoporosis or nonvertebral fractures








Drugs (hypnotics, antihypertension drugs)
Risk factors for both fracture and osteoporosis
General factors
Age $50 yr old
Women




Cumulative dose of corticosteroids
Biologic abnormalities
Vitamin D deﬁciency
Parathyroid hormone .130 ng/L
High serum ﬁbroblast growth factor 23 level
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GCs induce a net loss of BMD by reduction in bone
formation and bone density, especially in the trabecular
bone of the axial skeleton (12), which is related to the cu-
mulative dose exposure in kidney transplant recipients
(17). GCs have a profound inhibitory effect on bone for-
mation by targeting osteoblast proliferation and differen-
tiation while stimulating apoptosis of both osteoblasts and
osteocytes. GCs also have indirect effects on the skeleton
by inhibiting the synthesis of testosterone, estrogen, and
adrenal androgens.
However, the increased risk of bone loss post-
transplantation persists even in a steroid-free era. For
instance, in a recent study of 47 kidney transplant
recipients where GCs were withdrawn 3 days after
transplantation, BMD declined signiﬁcantly at the distal
radius at 12 months, although lumbar and hip BMDs did
not decline (18). This discrepancy between central and
peripheral skeleton seems to be associated with differ-
entially catabolic effects of parathyroid hormone (PTH)
rather than GC dosage. It is worth noting that, in immu-
nologically high–risk recipients, steroid-free immuno-
suppression may be associated with an increased risk
of rejection and therefore, paradoxically, increase the
risk of high–dose pulsed GCs.
Calcineurin inhibitors have been shown to increase PTH
and decrease magnesium. The increase in PTH results in an
increase in osteoclastic activity, which may further increase
the risk of osteoporosis (2).
Changes in Mineral Metabolism Post-Transplantation
A number of key changes in mineral metabolism occur in
the post-transplant period, although it is important to
recognize that the relationships between mineral abnor-
malities and graft/patient outcomes are, as yet, associative
rather than causal, and one cannot assume that changes in
mineral metabolism per se cause adverse outcomes. At pre-
sent, the clinical utility of serum markers of bone turnover
(PTH, bone–speciﬁc alkaline phosphatase [bALP],
osteocalcin) is limited in terms of adequate sensitivity
and speciﬁcity in predicting bone loss or bone structure
and function.
PTH decreases by 50% 6months after transplantation but
remains high in nearly 45% of kidney transplant recipients
2 years post-transplantation (19) because of improvements
in calcium, phosphorus, and 1,25–dihydroxy vitamin D
[1,25(OH)2D] levels associated with improving kidney
function (20). High PTH values correlate with signiﬁcant
bone loss at the hip (21), with PTH preferentially catabolic
toward cortical rather than trabecular bone. In a single-
center study of .140 kidney transplant recipients, persis-
tent hyperparathyroidism (PTH.130 ng/L) at 3 months was
an independent risk factor for fracture, with a 7.5-fold in-
crease in fracture risk (22). Furthermore, a recent analysis of
1609 kidney transplant recipients showed that persistent hy-
perparathyroidism was independently associated with
worse graft survival (19). Despite this strong observational
evidence linking high PTH levels to adverse outcomes, the
optimal post–transplantation PTH level remains unknown.
Calcium. Serum calcium usually follows a biphasic
pattern after kidney transplantation with an initial fall in
calcium level in the ﬁrst few weeks, probably secondary to
the signiﬁcant fall in PTH seen after transplantation. This is
followed by a rise in serum calcium reﬂecting a combina-
tion of increased 1,25(OH)2D production from the allograft
and persistent SHPT. Hypercalcemia has been reported in
around 5%–15% of patients after transplantation and is
most prevalent 3–6 months after transplantation, particu-
larly in patients with high PTH (20). Persistently high
Figure 1. | Pathophysiology of bone loss and fractures before and after transplantation. BMD, bone mineral density; BMI, body mass index;
FGF23, fibroblast growth factor 23; 1,25(OH)2D, 1,25–dihydroxy vitamin D; PTH, parathyroid hormone; SHPT, secondary hyperparathyroidism.
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serum calcium and PTH levels are associated with interstitial
microcalciﬁcation and poorer long–term graft outcomes (2).
Phosphorous. Hypophosphatemia is common in the
early post–transplant period, and it occurs in #50% of in-
cident kidney transplant recipients (20). It is usually self-
limiting, reﬂecting an improvement in excretory kidney
function, elevated PTH levels, and an increase in renal
tubular sensitivity to PTH and ﬁbroblast growth factor
23. Hypophosphatemia has been associated with severe
alterations in bone turnover, such as a decrease in osteo-
blast activity and defective mineralization.
Vitamin D. Deﬁciency in 25–hydroxy vitamin D
(25-OHD) is seen in 30% of kidney transplant recipients
(23), and even if allograft function normalizes, 25-OHD
levels often remain low. This persistent 25-OHD deﬁciency
leads to hypocalcemia and abnormal bone mineralization
(23). Furthermore, low 25-OHD levels may be associated
with poor graft outcomes, including an increased risk of
acute cellular rejection (24), possibly through the immuno-
modulatory effect of vitamin D on the immune system,
which may be mediated through direct effects on T cells
and also, indirectly viamodiﬁcation of dendritic cell function
(23). A recent prospective study from France showed that
low 25-OHD levels 3 months after transplantation were in-
dependently associated with a lower measured GFR and a
higher risk for interstitial ﬁbrosis at 12 months (25). There
are no published randomized, controlled trials (RCTs) of
native 25-OHD supplementation, but unpublished data
from the VITA-D Study (26) seem to suggest that supple-
mentation had no effect on either graft function or BMD.
Evaluating Fracture Risk
Role of DXA and Other Imaging in Fracture Risk
A DXA scan is a relatively accurate, noninvasive, cost–
effective screening method for estimating bone mass, and it
seems to help predict fracture risk in kidney transplant recip-
ients. In a Swedish study of 238 kidney transplant recipients,
19% of patients had a fracture over a 12-year follow-up, and
those with osteopenia and osteoporosis at the hip had a sig-
nificantly increased risk of fracture compared with those with
normal BMD (relative risks of 2.7 [95% conﬁdence interval,
1.6 to 4.6] and 3.5 [95% conﬁdence interval, 1.8 to 6.4],
respectively) (27).
DXA is unable to assess microarchitectural structure
of the bone and provides only a two-dimensional mea-
surement of bone density. In contrast, high–resolution
peripheral quantitative computed tomography (HR-
pQCT) of the distal tibia and radius provides microarch-
itectural information and is able to quantify volumetric
density of cortical and trabecular bone (28). Iyer et al. (18)
have used HR-pQCT to show signiﬁcant reductions in
both cortical and trabecular bone densities after trans-
plantation, which resulted in reduced estimated bone
strength. Presently, HR-pQCT is a promising research
tool, but there have been no studies to show whether it
is a better predictor of fracture than DXA in kidney
transplant recipients.
Fracture Risk Assessment
The Fracture Risk Assessment Tool (FRAX) accurately
estimates the 10-year probability of major osteoporotic
fractures in the general population and generates recom-
mendations for therapy in patients at high risk of fracture.
The FRAX does not require bone densitometry data to
predict fracture risk and therefore, is a potentially attractive
clinical decision aid. Recently, the FRAX has been shown to
modestly predict fracture risk in kidney transplant recip-
ients at a single center (29), but additional validation is
required before it can be used as a bedside tool.
Bone Biopsy
Bone biopsy with double-tetracycline labeling is the gold
standard to accurately diagnose post–transplantation bone
disease subtype, but it is not often performed. The Kidney
Disease Improving Global Outcomes (KDIGO) CKD-MBD
guideline (30) states that it is reasonable to consider bone bi-
opsy to guide treatment in the ﬁrst 12 months post-transplant,
but this recommendation is not graded because of a lack of
evidence. Ideally, kidney transplant recipients who have
persistent bone pain, fragility fractures, or severe osteoporo-
sis need a bone biopsy to exclude ABD before initiation of
antiresorptive therapy, because PTH levels are poorly pre-
dictive of underlying bone turnover (30). However, it is im-
portant to recognize that many patients ﬁnd this invasive
procedure unacceptable, and the processing and analysis of
bone biopsies require signiﬁcant expertise that precludes its
widespread use. Furthermore, there are no published studies
looking at the predictive value of bone biopsies in identify-
ing kidney transplant recipients at risk of fracture. More
studies are needed to clarify the clinical utility of bone bi-
opsy on the practical management of post–transplantation
bone disease and the effect of antiresorptive therapy on bone
histology in this population.
Preventing and Managing Bone Disease
Post-Transplantation
Figure 2 summarizes an approach to managing post–
transplantation bone disease based on the KDIGO guide-
lines (30), although it is important to recognize that the
evidence on which these recommendations are made is
generally poor; therefore, management approach is inevi-
tably opinion based. Speciﬁc interventions discussed below
focus on recent data that help inform our understanding of
these therapeutic strategies.
Minimizing GCs
Reducing steroid exposure can minimize bone loss and
should be especially considered for patients with known
pretransplant osteopenia or osteoporosis (30). In a study of 87
kidney transplant recipients, BMD improved at the lumbar
spine (by 4.7%) and the total hip (by 2.4%) after GC with-
drawal 1-year post-transplantation compared with those who
remained on GCs (31), and even late GC withdrawal has been
shown to improve BMD (32). A recent analysis of the USRDS
data found that early steroid withdrawal at hospital discharge
was associated with a 31% fracture risk reduction and lower
fracture–related hospitalization (10) without an increased risk
of rejection in the steroid withdrawal arm.
Vitamin D and Vitamin D Analogs
Supplementation with both active [1,25(OH)2D] and na-
tive (25-OHD) vitamin D can reduce loss of BMD in both
4 Clinical Journal of the American Society of Nephrology
the femoral and lumbar regions, but these studies have not
been sufﬁciently powered to determine whether there is a
beneﬁcial effect on fracture rate (23). Furthermore, vitamin
D has well described pleiotropic effects on the renin-
angiotensin-aldosterone system and proteinuria (23) and
immune-modulatory effects on T cells and dendritic cells,
which may affect graft function (25).
Paricalcitol, a synthetic metabolically active vitamin D
analog of calcitriol, has been shown to suppress PTH post-
transplantation but was associated with a higher risk of
hypercalcemia (33). In the same study, moderate renal al-
lograft ﬁbrosis was reduced in the paricalcitol group com-
pared with the control group. Another randomized,
crossover study has shown that paricalcitol also reduced
bone remodeling as reﬂected by reduction of bALP and
osteocalcin together with improvements in lumbar spine
BMD (34). Interestingly, there was a reduction in eGFR
associated with paricalcitol therapy, but it is not clear
whether this reﬂects changes in creatinine secretion and
generation or a direct effect on GFR.
Calcimimetics
Cinacalcet is a calcimimetic agent that increases the
sensitivity to calcium of the calcium-sensing receptor in the
parathyroid gland and suppresses PTH. A recent RCT for
the treatment of hypercalcemia and SHPT in 114 kidney
transplant recipients (35) showed that cinacalcet signiﬁ-
cantly reduced PTH and calcium with an increase in serum
phosphorus levels without any effect on graft function
compared with placebo. Although PTH has a catabolic
effect on bone, reducing PTH with cinacalcet, perhaps sur-
prisingly, had no positive effect on BMD, possibly because
of direct effects on a calcium-sensing receptor in bone that
may offset any beneﬁcial effects of lower PTH levels (36).
Cinacalcet therapy does result in signiﬁcant hypercalciuria
and may cause nephrocalcinosis, although this was not
seen in a cohort of 34 kidney transplant recipients who
underwent an allograft biopsy at 3 and 12 months post-
transplantation (37). The direct effect of cinacalcet on the bone
histomorphometry in kidney transplant recipients has not
been studied in detail. In a small study of kidney transplant
recipients who underwent bone biopsy before and after starting
cinacalcet, Borchhardt et al. (38) found that, although bone
formation rates fell in seven of 10 patients, ﬁve of 10 patients
had undetectable bone turnover after 18–24 months of cinacalcet
therapy. Notwithstanding the risk of ABD associated with
cinacalcet, one needs to recognize the risks associated with
parathyroidectomy in kidney transplant recipients. These in-
clude irreversibly inducing ABD and a decline in eGFR after
parathyroidectomy in the allograft, possibly as a result of the
direct effects of PTH on renal hemodynamics (39).
Recombinant PTH
Recombinant PTH (teriparatide) is an anabolic agent,
which can improve BMD in patients with GC-induced and
postmenopausal osteoporosis. In a 6-month double–blind
RCT of 26 kidney transplant recipients (40), patients who
received daily teriparatide injection did not show an im-
provement of BMD in the lumbar spine or distal radius
compared with those in the placebo group. However, there
was stabilization of femoral neck BMD in the teriparatide-
treated group. Teriparatide is expensive, and in view of
the lack of supporting data from RCTs in kidney trans-
plant recipients, its therapeutic role is unclear, although
theoretically, it may be an attractive agent for those with
severe osteoporosis who also have evidence of ABD.
Antiresorptive Agents
Bisphosphonates and denosumab are the two commonly
used antiresorptive agents for osteoporosis. Both therapies
can potentially induce low bone turnover, and therefore, it
is important to consider a bone biopsy before initiating
therapy in those at high risk of ABD, such as those who
have had a previous parathyroidectomy (30).
Bisphosphonates accumulate at sites of active bone re-
sorption, where they enter osteoclasts and inhibit farnesyl
pyrophosphate synthase, which results in osteoclast apo-
ptosis, thereby inhibiting bone resorption. They bind
potently to mineralized bone, with a half-life of #10 years,
and the fraction not taken up by bone (40%–60%) is
Figure 2. | Management of mineral and bone disorders post-transplantation. The strength of recommendation is indicated as level 1 (we
recommend), level 2 (we suggest), or not graded, and the quality of the supporting evidence is shown as A (high), B (moderate), C (low), or D
(very low). ABD, dynamic bone disease; BMD, bone mineral density; DXA, dual x-ray absorptiometry; KDIGO, Kidney Disease Improving
Global Outcomes; PTH, parathyroid hormone; SHPT, secondary hyperparathyroidism.
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excreted by a combination of glomerular ﬁltration and active
tubular transport. Therefore, impaired graft function can
have a signiﬁcant effect on the pharmacokinetics and half-
life of bisphosphonates. However, treatment is well tolerated
in kidney transplant recipients with a GFR.30 ml/min per
1.73 m2, with no signiﬁcant adverse effects compared with
placebo/no treatment (30).
The key RCTs using bisphosphonates in kidney trans-
plant recipients are summarized in Table 2 (41–52). Most of
the studies show that bisphosphonate therapy preserves or
increases BMD in the lumbar spine and femoral neck in the
early post–transplantation period. It is worth noting that
the risk of ABD as a result of bisphosphonate therapy has
not been a consistently observed phenomenon. For exam-
ple, Coco et al. (46) studied the effect of pamidronate com-
bined with low‐dose calcium and calcitriol on preservation
of bone mass at 6 and 12 months compared with placebo.
Pamidronate was associated with preservation of vertebral
BMD but an increased risk of low bone turnover on bone
biopsy. In contrast, more recent data from the same group
showed that risedronate did not affect BMD and that it
was not associated with an increased risk of developing
ABD in kidney transplant recipients (52). This difference
between bisphosphonate effects could be related to differ-
ences in potency in their mechanisms of action or may
reﬂect the difference in the enzyme-suppressive activity
of second (pamidronate) and third generation (risedronate)
bisphosphonates.
A recent study by Smerud et al. (51) showed no beneﬁt
with ibandronate compared with calcium and calcitriol
supplementation alone on lumbar BMD, but ibandronate
did modestly increase hip and forearm BMD. It also
suppressed bone turnover markers, including procollagen
type 1 N–terminal propeptide, osteocalcin, and bALP. This
ﬁnding is in striking contrast to earlier studies, which
seemed to show a beneﬁcial effect of bisphosphonates on
lumbar BMD. This is likely to be because of signiﬁcantly
less GC exposure in the study by Smerud et al. (51) as well
as the fact that the control group received calcitriol and
calcium supplementation. Indeed, a number of studies in
which vitamin D therapy was part of standard care in the
control group failed to show a beneﬁt of bisphosphonates
on BMD after kidney transplantation. This suggests that
widespread bisphosphonate use may have less of an effect
on BMD in the contemporary era of reduced rejection
rates, reduced steroid exposure, and widespread use of
vitamin D and that the value of bisphosphonate therapy
will be targeted use in high-risk recipients.
Denosumab, a humanized monoclonal antibody against
the receptor activator of NF-kB ligand, decreases bone re-
sorption, signiﬁcantly increases BMD, and decreases the
risk of vertebral, nonvertebral, and hip fractures in women
with osteoporosis. It is also effective at reducing fracture
risk in patients with impaired kidney function, including
those with CKD stage 4 (53). Denosumab is not renally
cleared, which makes it more attractive than bisphosphonates
in patients with signiﬁcant graft dysfunction, although
there are little data of its use in the transplant population.
Conclusions
Complex abnormalities of mineral homeostasis and bone
remodeling occur post-transplantation, resulting in loss
of bone density, increased risk of fracture, and increased
overall risk of mortality. All transplant recipients should be
evaluated for mineral bone disorder and monitored for
ongoing bone loss. Management of post–transplantation
bone disease is challenging but should initially focus on
biochemical abnormalities associated with bone mineral
disorder. Cinacalcet seems to be effective in correcting bio-
chemical abnormalities associated with hyperparathyroidism,
but it has no effect on BMD, and there are no outcome data
with regard to its effect on fracture risk. Similarly, although
DXA seems to predict fracture risk and bisphosphonates gen-
erally have a positive effect on BMD after transplantation,
there are little data to show that bisphosphonates effect clinical
end points, such as fracture. Reducing cumulative GC expo-
sure combined with calcium and vitamin D supplementation
alone prevents bone loss after transplantation. Antiresorptive
therapy, such as bisphosphonates, should only be reserved for
those patients at high risk of fracture with evidence of signif-
icant bone loss, despite optimal supportive therapy.
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